# Erbitux in Combination With Xeloda and Cisplatin in Advanced Esophago-gastric Cancer

> **NCT00678535** · PHASE3 · COMPLETED · sponsor: **Merck KGaA, Darmstadt, Germany** · enrollment: 904 (actual)

## Conditions studied

- Gastric Cancer

## Interventions

- **DRUG:** Cetuximab
- **DRUG:** Capecitabine
- **DRUG:** Cisplatin

## Key facts

- **NCT ID:** NCT00678535
- **Lead sponsor:** Merck KGaA, Darmstadt, Germany
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-06
- **Primary completion:** 2012-03
- **Final completion:** 2013-02
- **Target enrollment:** 904 (ACTUAL)
- **Last updated:** 2014-07-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00678535

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00678535, "Erbitux in Combination With Xeloda and Cisplatin in Advanced Esophago-gastric Cancer". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT00678535. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*